Halozyme Therapeutics, Inc. (HALO) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $82.97 (-0.43%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Dec 4, 2025 | Corinne Jenkins | Goldman Sachs | $56.00 | -32.5% |
| May 14, 2025 | Sean Laaman | Morgan Stanley | $62.00 | -25.3% |
| Nov 15, 2024 | Joseph Catanzaro | Piper Sandler | $52.00 | -37.3% |
| Jun 7, 2024 | Mitchell Kapoor | H.C. Wainwright | $65.00 | -21.7% |
| Jun 7, 2024 | Joseph Catanzaro | Piper Sandler | $51.00 | -38.5% |
| Jun 7, 2024 | Mohit Bansal | Wells Fargo | $58.00 | -30.1% |
| Jun 6, 2024 | Corinne Jenkins | Goldman Sachs | $44.00 | -47.0% |
Top Analysts Covering HALO
HALO vs Sector & Market
| Metric | HALO | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.20 | 2.25 | 2.42 |
| Analyst Count | 5 | 8 | 19 |
| Target Upside | +7.9% | +16366.1% | +18.0% |
| P/E Ratio | 33.32 | 2.98 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $445M | $468M | $481M | 2 |
| 2026-12-31 | $500M | $526M | $541M | 3 |
| 2027-03-31 | $445M | $469M | $482M | 3 |
| 2027-06-30 | $449M | $472M | $485M | 2 |
| 2027-09-30 | $452M | $475M | $489M | 2 |
| 2027-12-31 | $455M | $479M | $492M | 3 |
| 2028-12-31 | $2.16B | $2.16B | $2.16B | 4 |
| 2029-12-31 | $1.96B | $2.00B | $2.02B | 3 |
| 2030-12-31 | $1.74B | $1.77B | $1.80B | 3 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-09-30 | $2.06 | $2.20 | $2.28 | 1 |
| 2026-12-31 | $2.35 | $2.51 | $2.60 | 2 |
| 2027-03-31 | $2.05 | $2.19 | $2.27 | 2 |
| 2027-06-30 | $2.29 | $2.44 | $2.53 | 1 |
| 2027-09-30 | $2.40 | $2.56 | $2.65 | 1 |
| 2027-12-31 | $2.47 | $2.65 | $2.74 | 2 |
| 2028-12-31 | $10.97 | $10.98 | $11.00 | 2 |
| 2029-12-31 | $9.84 | $10.10 | $10.26 | 1 |
| 2030-12-31 | $8.62 | $8.85 | $8.99 | 1 |
Frequently Asked Questions
What is the analyst consensus for HALO?
The consensus among 5 analysts covering Halozyme Therapeutics, Inc. (HALO) is Buy with an average price target of $88.25.
What is the highest price target for HALO?
The highest price target for HALO is $65.00, set by Mitchell Kapoor at H.C. Wainwright on 2024-06-07.
What is the lowest price target for HALO?
The lowest price target for HALO is $44.00, set by Corinne Jenkins at Goldman Sachs on 2024-06-06.
How many analysts cover HALO?
5 analysts have issued ratings for Halozyme Therapeutics, Inc. in the past 12 months.
Is HALO a buy or sell right now?
Based on 5 analyst ratings, HALO has a consensus rating of Buy (2.20/5) with a +7.9% upside to the consensus target of $88.25.
What are the earnings estimates for HALO?
Analysts estimate HALO will report EPS of $2.20 for the period ending 2026-09-30, with revenue estimated at $468M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.